Biotalk
Biotalk Episode 38: 2026 Q3 Report: Global Trends in Biopharma Transactions
12:13
M&A has already topped all of 2025, and China still holds 58% of global licensing value.
In Episode 38 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q3 Report: Global Trends in Biopharma Transactions.
Licensing: $48B across 41 deals. Value fell 33% from Q2 on just a 5% drop in volume: the story was deal size, as Q2’s megadeals rolled off. Upfronts rebounded to 10% of deal…